Last reviewed · How we verify

Onartuzumab (MetMab) — Competitive Intelligence Brief

Onartuzumab (MetMab) (Onartuzumab (MetMab)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MET inhibitor monoclonal antibody. Area: Oncology.

phase 3 MET inhibitor monoclonal antibody MET (hepatocyte growth factor receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Onartuzumab (MetMab) (Onartuzumab (MetMab)) — Genentech, Inc.. Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Onartuzumab (MetMab) TARGET Onartuzumab (MetMab) Genentech, Inc. phase 3 MET inhibitor monoclonal antibody MET (hepatocyte growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MET inhibitor monoclonal antibody class)

  1. Genentech, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Onartuzumab (MetMab) — Competitive Intelligence Brief. https://druglandscape.com/ci/onartuzumab-metmab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: